Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

803.17 +19.52 (+2.49%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

59 60 Next >

Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

March 25, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls ↗

March 24, 2025

Unity diabetes study showing durable vision gains with full 36-week data expected in Q2 2025.

Via Benzinga

Opthea Phase 3 Trial Fails To Meet Primary Endpoint, Faces Financial Uncertainty ↗

March 24, 2025

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces potential investor obligations.

Via Benzinga

3 Reasons to Sell REGN and 1 Stock to Buy Instead

March 21, 2025

What a brutal six months it’s been for Regeneron. The stock has dropped 39.3% and now trades at $662.80, rattling many shareholders. This might have investors contemplating their next move.

Via StockStory

1 Dividend Stock Down 30% to Buy and Hold for the Next Decade ↗

March 09, 2025

Via The Motley Fool

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

March 20, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers.

Via StockStory

Topics Artificial Intelligence

Price Over Earnings Overview: Regeneron Pharmaceuticals ↗

March 18, 2025

Via Benzinga

2 Large-Cap Stocks with Solid Fundamentals and 1 to Brush Off

March 17, 2025

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for...

Via StockStory

Friday's session: top gainers and losers in the S&P500 index ↗

March 14, 2025

Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

These S&P500 stocks are gapping in today's session ↗

March 14, 2025

Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Friday and stay ahead of the market trends.

Via Chartmill

3 Stocks With Ironclad Balance Sheets for Long-Term Stability

March 13, 2025

Check out these three stocks with balance sheets that have a case for being among the strongest in the entire stock market.

Via MarketBeat

Topics Economy Supply Chain

What's going on in today's session: S&P500 gap up and gap down stocks ↗

March 12, 2025

Curious about the market action on Wednesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.

Via Chartmill

Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem

March 11, 2025

$250,000 top award goes to Matteo Paz in America’s longest running and most distinguished science and math competition

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Which S&P500 stocks are moving on Monday? ↗

March 10, 2025

Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

REGN DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – REGN

March 10, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

March 10, 2025

From The Schall Law Firm

Via Business Wire

Top S&P500 movers in Monday's session ↗

March 10, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study ↗

March 10, 2025

Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints in IGNITE and SHUTTLE studies.

Via Benzinga

REGN Deadline: Rosen Law Firm Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

March 08, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

March 08, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Deadline Soon: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

March 07, 2025

From The Law Offices of Frank R. Cruz

Via Business Wire

Eli Lilly's Single Monthly Maintenance Shot Of Eczema Drug Shows Completely Clear Skin At 3 Years In 50% Of Trial Patients ↗

March 07, 2025

Eli Lilly's Ebglyss showed sustained eczema relief, with 50% achieving full skin clearance and 87% maintaining near-clear skin over three years.

Via Benzinga

Faruqi & Faruqi Reminds Regeneron Pharmaceutials Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN

March 07, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

REGN DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important March 10 Deadline in Securities Class Action – REGN

March 04, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Biotech Rally Coming In Weeks Ahead? ↗

March 04, 2025

Large cap biopharma and MedTech stocks are leading the healthcare sector higher.

Via Talk Markets

Topics ETFs Stocks / Equities

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals

March 03, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial ↗

March 03, 2025

Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent.

Via Benzinga

DEADLINE NEXT WEEK: Berger Montague Advises Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors to Contact the Firm Before March 10, 2025

March 03, 2025

From Berger Montague

Via GlobeNewswire

REGENERON THERAPEUTICS, INC. (NASDAQ: REGN) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Regeneron Therapeutics, Inc. Investors of Upcoming Deadline

March 03, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

February 28, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Regeneron Pharmaceuticals (NQ:REGN)

All News about Regeneron Pharmaceuticals

Starting at $3.75/week.

Subscribe Today